• Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients
  • Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago.